JOINN Laboratories (06127) rose more than 5% against the broader market trend during intraday trading, and as of press time, the stock was up 3.93% at HK$30.66, with a turnover of HK$209 million.

According to publicly available information, JOINN Laboratories (06127) has indirectly acquired a stake in Jianda Jiuzhou through the North Brain Phase I Fund, deeply anchoring itself to the optogenetics pipeline. On the other hand, the company possesses non-clinical safety evaluation CRO capabilities and operates a non-human primate animal model platform, enabling it to undertake toxicology testing and circuit validation evaluation services for central nervous system novel drugs following the localization of neural circuits using optogenetics technology.

Huatai Securities previously noted that the company's total order backlog in hand for the first half of the year amounted to approximately RMB 3.7 billion, representing a year-on-year increase of 60.9%, while newly signed orders reached approximately RMB 2.02 billion, up 98.0% year-on-year. Of this, newly signed orders in 2Q26 totaled approximately RMB 1.11 billion. Order performance has continued to be impressive, further enhancing the visibility of future earnings.

Considering the positive recovery in domestic industry demand, combined with the company's ongoing overseas business expansion, Huatai Securities is optimistic about the company's medium-to-long-term growth potential. Both the company's A-shares and H-shares maintain a "Buy" rating.